John Gerich

Summary

Publications

  1. ncbi Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Am J Physiol Endocrinol Metab 290:E67-E77. 2006
  2. ncbi Postprandial hyperglycemia and cardiovascular disease
    John E Gerich
    Department of Medicine, University of Rochester, New York, USA
    Endocr Pract 12:47-51. 2006
  3. pmc Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk
    Ajikumar V Aryangat
    University of Rochester, Rochester, New York 14642, USA
    Vasc Health Risk Manag 6:145-55. 2010
  4. ncbi Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?
    John E Gerich
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Diabetes 51:S117-21. 2002
  5. ncbi Insulin glargine: long-acting basal insulin analog for improved metabolic control
    John E Gerich
    School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
    Curr Med Res Opin 20:31-7. 2004
  6. ncbi The importance of tight glycemic control
    John E Gerich
    University of Rochester School of Medicine, Rochester, New York 14642, USA
    Am J Med 118:7S-11S. 2005
  7. ncbi Hepatorenal glucose reciprocity in physiologic and pathologic conditions
    J E Gerich
    University of Rochester School of Medicine, Department of Medicine, Rochester, NY 14642, USA
    Diabetes Nutr Metab 15:298-302; discussion 302-3. 2002
  8. ncbi Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk
    John E Gerich
    General Clinical Research Center, University of Rochester, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
    Diabetes Educ 32:513-4, 520-2. 2006
  9. ncbi The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk
    John E Gerich
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Curr Med Res Opin 23:1791-8. 2007
  10. ncbi Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors
    John E Gerich
    Endocrinology and Metabolism Unit, University of Rochester School of Medicine, Rochester, New York 14627, USA
    Clin Cornerstone 8:53-68. 2007

Collaborators

Detail Information

Publications48

  1. ncbi Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Am J Physiol Endocrinol Metab 290:E67-E77. 2006
    ..g., liver and muscle) into other tissues...
  2. ncbi Postprandial hyperglycemia and cardiovascular disease
    John E Gerich
    Department of Medicine, University of Rochester, New York, USA
    Endocr Pract 12:47-51. 2006
    ..To review the role of postprandial hyperglycemia in the development of type 2 diabetes mellitus and cardiovascular disease...
  3. pmc Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk
    Ajikumar V Aryangat
    University of Rochester, Rochester, New York 14642, USA
    Vasc Health Risk Manag 6:145-55. 2010
    ....
  4. ncbi Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?
    John E Gerich
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Diabetes 51:S117-21. 2002
    ....
  5. ncbi Insulin glargine: long-acting basal insulin analog for improved metabolic control
    John E Gerich
    School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
    Curr Med Res Opin 20:31-7. 2004
    ..This review describes the unique pharmacokinetic properties and clinical efficacy of insulin glargine...
  6. ncbi The importance of tight glycemic control
    John E Gerich
    University of Rochester School of Medicine, Rochester, New York 14642, USA
    Am J Med 118:7S-11S. 2005
    ..Meal-related self-monitoring of blood glucose can inform patients and their healthcare providers about postprandial glycemic excursions so that diet, exercise, or medications can be adjusted...
  7. ncbi Hepatorenal glucose reciprocity in physiologic and pathologic conditions
    J E Gerich
    University of Rochester School of Medicine, Department of Medicine, Rochester, NY 14642, USA
    Diabetes Nutr Metab 15:298-302; discussion 302-3. 2002
  8. ncbi Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk
    John E Gerich
    General Clinical Research Center, University of Rochester, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
    Diabetes Educ 32:513-4, 520-2. 2006
    ..Case studies are presented to aid clinicians in helping patients learn how to measure and control their postprandial glucose levels...
  9. ncbi The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk
    John E Gerich
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Curr Med Res Opin 23:1791-8. 2007
    ..Recent studies suggest that newer therapies specifically targeting postprandial hyperglycemia can significantly reduce postprandial glucose levels and improve overall glycemic control...
  10. ncbi Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors
    John E Gerich
    Endocrinology and Metabolism Unit, University of Rochester School of Medicine, Rochester, New York 14627, USA
    Clin Cornerstone 8:53-68. 2007
    ....
  11. doi Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus
    John E Gerich
    University of Rochester, School of Medicine, Rochester, NY 14642, USA
    Expert Rev Clin Pharmacol 4:669-83. 2011
    ..Unexpected numerical imbalances between dapagliflozin and comparator were noted for breast and bladder cancers. The potential for increased cancer risk with dapagliflozin needs to be further assessed...
  12. ncbi Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology
    J E Gerich
    Department of Medicine, Physiology and Pharmacology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Eur J Clin Invest 32:46-53. 2002
    ....
  13. ncbi Renal gluconeogenesis: its importance in human glucose homeostasis
    J E Gerich
    Department of Medicine, University of Rochester, New York 14642, USA
    Diabetes Care 24:382-91. 2001
    ....
  14. ncbi Is insulin resistance the principal cause of type 2 diabetes?
    J E Gerich
    University of Rochester School of Medicine, NY 14642, USA
    Diabetes Obes Metab 1:257-63. 1999
    ..Furthermore, it is not known whether pharmacologic agents which improve insulin sensitivity have similar effects...
  15. ncbi Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
    J E Gerich
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Diabet Med 27:136-42. 2010
    ..Specific SGLT2 inhibitors are being developed as a novel means of controlling hyperglycaemia in T2DM...
  16. ncbi Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans
    Christian Meyer
    Department of Medicine, University of Roichester School of Medicine, Rochester, NY 14642, USA
    Am J Physiol Endocrinol Metab 285:E819-26. 2003
    ....
  17. ncbi Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA
    Metabolism 51:1494-500. 2002
    ..04) and was similar to DM(-) (7.3 +/- 0.5 mL x kg(-1) x min(-1), P >.9). We conclude that in contrast to the excessive HGR, excessive RGR and impaired FFA clearance are not corrected by acute exogenous insulin replacement...
  18. ncbi Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes
    Mary Korytkowski
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Diabetes Care 25:1607-11. 2002
    ..The purpose of this study was to assess the effect of glimepiride on insulin sensitivity and secretion in subjects with type 2 diabetes...
  19. ncbi Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM)
    J E Gerich
    University of Rochester, Medical Center, New York, USA
    Horm Metab Res 28:404-12. 1996
    ....
  20. doi DPP-4 inhibitors: what may be the clinical differentiators?
    John Gerich
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Diabetes Res Clin Pract 90:131-40. 2010
    ..This review offers an overview of DPP-4 inhibitors in T2DM and suggests some characteristics that may provide clinically relevant differentiators within this class...
  21. ncbi PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin
    John Gerich
    General Clinical Research Center, University of Rochester, New York, USA
    Diabetes Care 28:2093-9. 2005
    ..To compare long-term efficacy and safety of initial combination therapy with nateglinide/metformin versus glyburide/metformin...
  22. ncbi Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine
    John Gerich
    University of Rochester Medical Center, Rochester, New York, USA
    Diabetes Technol Ther 8:237-43. 2006
    ..The large fluctuations in blood concentrations and activity observed with insulin therapies such as NPH insulin or insulin ultralente may result in hyper- or hypoglycemia...
  23. ncbi Renal substrate exchange and gluconeogenesis in normal postabsorptive humans
    Christian Meyer
    Department of Medicine and Physiology, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Am J Physiol Endocrinol Metab 282:E428-34. 2002
    ....
  24. ncbi Matching treatment to pathophysiology in type 2 diabetes
    J E Gerich
    Department of Medicine, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    Clin Ther 23:646-59; discussion 645. 2001
    ..CONCLUSIONS: Current research suggests that early aggressive treatment with combination therapy achieves glycemic control at lower doses and with fewer side effects than monotherapy with either component...
  25. ncbi Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease
    H Mieszczanska
    Cardiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Thromb Haemost 5:942-9. 2007
    ..To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease...
  26. ncbi Clinical significance, pathogenesis, and management of postprandial hyperglycemia
    John E Gerich
    Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Arch Intern Med 163:1306-16. 2003
    ..This review summarizes epidemiologic and experimental studies linking postprandial hyperglycemia to cardiovascular disease and therapeutic approaches available and in development to treat this disorder...
  27. ncbi Pathways for glucose disposal after meal ingestion in humans
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Am J Physiol Endocrinol Metab 284:E716-25. 2003
    ..The majority of glycogen is formed via the direct pathway ( approximately 73%)...
  28. ncbi Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels
    Hans J Woerle
    Department of Internal Medicine II, Clinical Research Unit CRU, Ludwig Maximilian University Munich, Grosshadern Marchioninistr 15, Munich 81377, Germany
    Diabetes Res Clin Pract 77:280-5. 2007
    ..Cross-sectional studies suggest that attainment of HbA1c goals requires specific targeting of postprandial hyperglycemia...
  29. ncbi The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications
    Beth Elaine Dunning
    PharmaWrite, Princeton, New Jersey 08540, USA
    Endocr Rev 28:253-83. 2007
    ....
  30. ncbi Novel insulins: expanding options in diabetes management
    John E Gerich
    Department of Medicine, Physiology, and Pharmacology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Am J Med 113:308-16. 2002
    ..Other long-acting analogs, such as fatty acid acylated insulins, have been tested in animal models and are being evaluated in clinical studies...
  31. ncbi Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Diabetes 52:1386-92. 2003
    ....
  32. ncbi Autoregulation of endogenous glucose production during hyperglucagonemia
    Ingrid Toft
    Institute of Clinical Medicine, University of Tromsø, Norway
    Metabolism 51:1128-34. 2002
    ..5 +/- 0.6 versus 11.6 +/- 0.6 micromol/kg/min (P =.19). We conclude that in normal volunteers, neither hyperglucagonemia nor the combination of hyperglucagonemia and increased substrate availability alters the autoregulation of EGP...
  33. ncbi Disturbances in beta-cell function in impaired fasting glycemia
    Timon W van Haeften
    Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Diabetes 51:S265-70. 2002
    ..05). We conclude that the early stages of glucose intolerance are associated with disturbances in beta-cell function, while insulin resistance is seen more markedly in later stages...
  34. ncbi Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis
    Christian Meyer
    Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Am J Physiol Endocrinol Metab 282:E419-27. 2002
    ..We postulate that increases in postprandial renal glucose release may play a role in facilitating efficient liver glycogen repletion by permitting substantial suppression of hepatic glucose release...
  35. ncbi Role of the kidney in hyperglycemia in type 2 diabetes
    Christian Meyer
    Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
    Curr Diab Rep 2:237-41. 2002
    ....
  36. ncbi Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance
    Ervin Szoke
    Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    Diabetes Care 31:539-43. 2008
    ..To examine the effect of aging on insulin secretion (first- and second-phase insulin release) and insulin sensitivity in people with normal glucose tolerance (NGT) or impaired glucose tolerance (IGT)...
  37. ncbi Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Arch Intern Med 164:1627-32. 2004
    ....
  38. ncbi Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes
    Christian Meyer
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Am J Physiol Endocrinol Metab 287:E1049-56. 2004
    ..The latter may provide an explanation for the renal glycogen accumulation characteristic of diabetes mellitus as well as a mechanism by which hyperglycemia may lead to diabetic nephropathy...
  39. ncbi Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus
    John E Gerich
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Mayo Clin Proc 78:447-56. 2003
    ..Therefore, clinicians managing type 2 diabetes must reduce insulin resistance and augment and/or replace beta-cell function...
  40. ncbi Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans
    Niyaz R Gosmanov
    Carl T Hayden VA Medical Center, 650 E Indian School Road, Phoenix, AZ 85012, USA
    Diabetes Care 28:1124-31. 2005
    ..However, in humans this role of decreased intraislet insulin is still unclear...
  41. ncbi Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus
    Ervin Szoke
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Compr Ther 31:106-12. 2005
    ..Targeting both insulin resistance and impaired insulin secretion is therefore appropriate to prevent T2DM and to improve glycemic control in those with the disorder...
  42. ncbi Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial
    Jay S Skyler
    University of Miami, School of Medicine, Miami, FL 33136, USA
    Diabetes Care 28:1630-5. 2005
    ..We investigated whether a basal/bolus insulin regimen involving rapid-acting, dry powder, inhaled insulin could provide glycemic control comparable with a basal/bolus subcutaneous regimen...
  43. ncbi Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    Diabetes 52:918-25. 2003
    ....
  44. ncbi Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes
    Zarmen Israelian
    Department of Endocrinology, Carl T Hayden VA Medical Center, Phoenix, AZ 85012, USA
    Diabetes Care 28:2691-6. 2005
    ..The present studies were therefore undertaken to test the hypothesis that these may be improved by increasing this decrement in insulin secretion...
  45. ncbi Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia
    Ervin Szoke
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Metabolism 55:78-83. 2006
    ..This differential effect on insulin secretion may be an important factor in explaining why glyburide causes severe hypoglycemia more frequently than glimepiride...
  46. pmc Advances in diabetes for the millennium: understanding insulin resistance
    John E Gerich
    Clinical Research Center, University of Rochester School of Medicine, Rochester, New York, USA
    MedGenMed 6:11. 2004
    ..Therefore, agents that improve beta-cell function (such as sulfonylureas and meglitinides) and insulin sensitizers (such as metformin and thiazolidinediones) both are useful alone or in combination for treating type 2 diabetes...
  47. ncbi Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus
    Zarmen Israelian
    Department of Endocrinology, Carl T Hayden VA Medical Center, Phoenix, AZ 85012, and Department of Medicine, University of Rochester School of Medicine, NY 14642, USA
    Metabolism 55:593-8. 2006
    ..These include delayed and reduced decreases in insulin secretion, and impaired increases of plasma glucagon and growth hormone...

Research Grants10

  1. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2006
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. [unreadable] [unreadable]..
  2. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2005
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. ..
  3. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2004
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. ..
  4. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2003
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. ..
  5. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2002
    ..Better understanding of the pathogenesis of hypoglycemia unawareness and abnormal glucose counterregulation should make treatment of diabetes safer and improve the chances of achieving optimal glycemic control. ..
  6. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 1999
    ..Better understanding of the pathogenesis of hypoglycemia unawareness and abnormal glucose counterregulation should make treatment of diabetes safer and improve the chances of achieving optimal glycemic control. ..
  7. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2007
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. [unreadable] [unreadable]..